Progyny (NASDAQ:PGNY) Updates Q2 2026 Earnings Guidance

Progyny (NASDAQ:PGNY - Get Free Report) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.500-0.53 for the period, compared to the consensus earnings per share estimate of 0.440. The company issued revenue guidance of $342.0 million-$355.0 million, compared to the consensus revenue estimate of $349.5 million. Progyny also updated its FY 2026 guidance to 1.980-2.09 EPS.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded up $0.46 during trading hours on Thursday, reaching $19.16. The stock had a trading volume of 1,827,030 shares, compared to its average volume of 1,499,703. Progyny has a 1 year low of $16.10 and a 1 year high of $28.75. The firm's 50 day moving average is $17.91 and its 200-day moving average is $21.69. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 29.48, a P/E/G ratio of 1.09 and a beta of 0.91.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.06. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Analysts forecast that Progyny will post 1.12 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on PGNY shares. Citizens Jmp raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $30.00 target price on the stock in a research report on Tuesday, January 20th. Zacks Research downgraded shares of Progyny from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. Barclays dropped their target price on shares of Progyny from $29.00 to $23.00 and set an "overweight" rating on the stock in a research report on Friday, March 20th. BTIG Research dropped their target price on shares of Progyny from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Thursday, March 5th. Finally, Truist Financial dropped their target price on shares of Progyny from $34.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.91.

Insider Transactions at Progyny

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company's stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 7,455 shares of company stock worth $129,515. Company insiders own 9.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PGNY. Royal Bank of Canada grew its position in Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock worth $291,000 after purchasing an additional 10,340 shares during the last quarter. Amundi lifted its stake in shares of Progyny by 103.8% in the 1st quarter. Amundi now owns 11,419 shares of the company's stock worth $264,000 after acquiring an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock worth $5,630,000 after acquiring an additional 14,297 shares during the period. Invesco Ltd. lifted its stake in shares of Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company's stock worth $8,342,000 after acquiring an additional 103,253 shares during the period. Finally, Walleye Capital LLC lifted its stake in shares of Progyny by 6.9% in the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company's stock worth $266,000 after acquiring an additional 780 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.